C
일동제약
249420KOSPI의약품 제조업43.1 / 100
Reference Date: 2026-04-13
Financial Score12.0 / 40
News Sentiment13.1 / 25
Momentum8.0 / 20
Disclosure10.0 / 15
AI Analysis: ROE significantly exceeds the industry average but the high debt ratio poses financial risk. Plunged 17.0% over the past month, and news sentiment is positive.
Company InformationBased on 2025 Annual Report
Business Overview
Il Dong Pharmaceutical is a company engaged in the manufacture and sale of pharmaceuticals, raw materials, and health supplements. Key products include Aronamin, Furumarin, and Laviert, with sales of 614,941 million won in the 9th fiscal year. Products are distributed domestically and internationally through channels such as wholesale, retail, and hospitals, with active R&D investments.
Number of Employees
1,104people
Average Salary
79.7M KRW
Score Calculation Basis
Detailed Financial Score
PER
28.77Industry Average 14.801.5Point
1.9x industry avg (risky)
PBR
3.58Industry Average 1.040.0Point
3.4x industry avg (risky)
ROE
11.89Industry Average 4.427.0Point
2.7x industry avg (excellent)
Debt Ratio
42.82Industry Average 11.980.0Point
3.6x industry avg (risky)
Trend 2023~20253.5 / 10 points
Revenue Growth Rate
0.5 / 3
Avg ▼2.7% (2-year basis)
Operating Profit Growth Rate
3.0 / 3
Avg ▲86.4% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -13.0% (improving, 3yr)
Detailed News Sentiment
27 totalPositive 6Neutral 16Negative 0Average Sentiment Score 53
- Neutral
- Neutral
- Neutral
Detailed Momentum
52-week position5.0Point
52w mid range (48%)
Current 27,100Won52-week high 44,30052-week low 11,140
1-month return0.0Point
1m -17.00% (strong drop)
Volume trend3.0Point
Volume flat
Detailed Disclosure
5 totalPositive 0Neutral 5Negative 0
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-03
- Neutral정기주주총회결과2026-03-26
- Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-26
- Neutral사업보고서 (2025.12)2026-03-18
- Neutral감사보고서제출2026-03-18